Pfizer Corporation

Bend Research, Inc.

James Blair West

Dwayne Thomas Friesen

Scott Max Herbig

Walter Christian Babcock

Bruce M Johnson

Ravi Mysore Shanker

William John Curatolo

James A S Nightingale

Douglas Alan Lorenz

David Keith Lyon

Scott B McCray

Marshall David Crew

Leah Elizabeth Appel

Julian B Lo

Kelly L Smith

Avinash G Thombre

Rodney James Ketner

Paul Van Eikeren

Michael Jon Gumkowski

Hylar Lewis Friedman

Ravi Mysore Shankar

Mary T Am Ende

Timothy A Hagen

Ravi Moysore Shanker

In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.

Pharmaceutical compositions of dispersions of drug and neutral polymers

The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.

Azithromycin dosage forms with reduced side effects

Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr.

Sertraline salts and sustained-release dosage forms of sertraline

Plasma discharge reactors of various designs are disclosed; the reactors are capable of synthesizing large numbers of bioactive compounds of great chemical diversity.

Plasma discharge reactors for the preparation of bioactive compounds

Large numbers of bioactive compounds of great chemical diversity may be rapidly prepared by subjecting organic compound mixtures to a plasma discharge, followed by screening for specific bioactivity.

Preparation of bioactive compounds by plasma synthesis

Supported liquid membrane delivery devices that release a beneficial agent to an aqueous environment following exposure to an environmental trigger. A microporous hydrophobic support membrane at least partially surrounds a beneficial agent- containing hydrophilic formulation. A hydrophobic liquid is held within the microporous support membrane by capillarity and the hydrophobic liquid is substantially permeable to the aqueous environment and the beneficial agent-containing hydrophilic formulation. The entrained hydrophobic liquid becomes substantially permeable to the aqueous environment upon exposure to an environmental trigger such as an enzyme, and the beneficial agent is subsequently released.

Supported liquid membrane delivery devices

Growing community of inventors

Bend, OR, United States of America

James Blair West